Trade Omnicell - OMCL CFD

Add to favourite

27.21

3.74%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.11

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Omnicell Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	26.23
Open*	26.25
1-Year Change*	-55.35%
Day's Range*	26.25 - 27.23
52 wk Range	28.72-77.14
Average Volume (10 days)	411.52K
Average Volume (3 months)	13.28M
Market Cap	1.49B
P/E Ratio	-100.00K
Shares Outstanding	45.47M
Revenue	1.19B
EPS	-0.77
Dividend (Yield %)	N/A
Beta	0.84
Next Earnings Date	Feb 8, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	27.21	0.95	3.62%	26.26	27.28	26.21
Apr 17, 2024	26.23	-0.31	-1.17%	26.54	26.76	26.09
Apr 16, 2024	26.57	0.18	0.68%	26.39	27.22	26.35
Apr 15, 2024	26.81	0.37	1.40%	26.44	27.26	26.44
Apr 12, 2024	27.14	0.08	0.30%	27.06	27.14	26.45
Apr 11, 2024	27.29	-0.23	-0.84%	27.52	27.62	27.11
Apr 10, 2024	27.38	0.23	0.85%	27.15	27.73	26.46
Apr 9, 2024	28.61	1.03	3.73%	27.58	28.94	27.07
Apr 8, 2024	27.87	0.36	1.31%	27.51	27.88	27.22
Apr 5, 2024	27.47	0.32	1.18%	27.15	27.75	27.14
Apr 4, 2024	27.56	0.00	0.00%	27.56	28.39	27.44
Apr 3, 2024	27.51	0.09	0.33%	27.42	27.90	27.16
Apr 2, 2024	27.69	-0.34	-1.21%	28.03	28.03	27.00
Apr 1, 2024	28.60	-0.62	-2.12%	29.22	29.22	28.27
Mar 28, 2024	29.18	1.25	4.48%	27.93	29.67	27.93
Mar 27, 2024	29.17	1.29	4.63%	27.88	29.17	27.88
Mar 26, 2024	27.85	-0.29	-1.03%	28.14	28.42	27.66
Mar 25, 2024	28.33	0.43	1.54%	27.90	28.38	27.88
Mar 22, 2024	27.90	-0.19	-0.68%	28.09	28.72	27.89
Mar 21, 2024	28.41	0.49	1.76%	27.92	28.87	27.87

Omnicell Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Omnicell Inc Earnings Call Q1 2024 Omnicell Inc Earnings Call Forecast - Previous -
Time (UTC) 12:30	Country US	Event Q1 2024 Omnicell Inc Earnings Release Q1 2024 Omnicell Inc Earnings Release Forecast - Previous -
Tuesday, May 21, 2024
Time (UTC) 16:00	Country US	Event Omnicell Inc Annual Shareholders Meeting Omnicell Inc Annual Shareholders Meeting Forecast - Previous -
Wednesday, May 22, 2024
Time (UTC) 20:30	Country US	Event Omnicell Inc Annual Shareholders Meeting Omnicell Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, July 30, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Omnicell Inc Earnings Release Q2 2024 Omnicell Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	1295.95	1132.02	892.208	897.027	787.309
Revenue	1295.95	1132.02	892.208	897.027	787.309
Cost of Revenue, Total	698.942	576.976	476.352	460.115	414.979
Gross Profit	597.005	555.042	415.856	436.912	372.33
Total Operating Expense	1298.27	1042.51	856.682	818.675	742.917
Selling/General/Admin. Expenses, Total	475.171	387.904	303.924	289.916	263.095
Research & Development	101.354	75.611	66.445	68.644	64.843
Operating Income	-2.323	89.507	35.526	78.352	44.392
Interest Income (Expense), Net Non-Operating	-0.13	-23.5	-6.177	-4.419	-8.776
Net Income Before Taxes	-2.453	66.007	29.349	73.933	35.616
Net Income After Taxes	5.648	77.849	32.194	61.338	37.729
Net Income Before Extra. Items	5.648	77.849	32.194	61.338	37.729
Total Extraordinary Items				0	0
Net Income	5.648	77.849	32.194	61.338	37.729
Income Available to Common Excl. Extra. Items	5.648	77.849	32.194	61.338	37.729
Income Available to Common Incl. Extra. Items	5.648	77.849	32.194	61.338	37.729
Diluted Net Income	5.648	77.849	32.194	61.338	37.729
Diluted Weighted Average Shares	45.891	47.943	43.743	42.943	40.559
Diluted EPS Excluding Extraordinary Items	0.12307	1.62378	0.73598	1.42836	0.93023
Diluted Normalized EPS	0.44606	1.79624	0.884	1.42836	0.99914
Unusual Expense (Income)	22.803	2.02	9.961
Dilution Adjustment			0

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	298.973	290.629	297.674	348.059	331.386
Revenue	298.973	290.629	297.674	348.059	331.386
Cost of Revenue, Total	164.292	165.456	168.503	188.52	173.294
Gross Profit	134.681	125.173	129.171	159.539	158.092
Total Operating Expense	291.225	313.592	336.031	329.594	318.901
Selling/General/Admin. Expenses, Total	103.082	120.429	123.382	114.381	119.252
Research & Development	23.13	22.393	26.664	24.899	26.355
Unusual Expense (Income)	0.721	5.314	17.482	1.794	0
Operating Income	7.748	-22.963	-38.357	18.465	12.485
Interest Income (Expense), Net Non-Operating	4.461	1.781	2.843	-1.148	-1.711
Net Income Before Taxes	12.209	-21.182	-35.514	17.317	10.774
Net Income After Taxes	3.451	-15	-28.408	16.774	9.069
Net Income Before Extra. Items	3.451	-15	-28.408	16.774	9.069
Net Income	3.451	-15	-28.408	16.774	9.069
Income Available to Common Excl. Extra. Items	3.451	-15	-28.408	16.774	9.069
Income Available to Common Incl. Extra. Items	3.451	-15	-28.408	16.774	9.069
Diluted Net Income	3.451	-15	-28.408	16.774	9.069
Diluted Weighted Average Shares	45.472	44.887	44.68	45.819	46.26
Diluted EPS Excluding Extraordinary Items	0.07589	-0.33417	-0.63581	0.36609	0.19604
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	0.0862	-0.25722	-0.38148	0.40402	0.19604

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	881.812	780.702	829.414	483.238	397.134
Cash and Short Term Investments	341.848	359.716	496.174	127.21	67.192
Cash
Cash & Equivalents	330.362	349.051	485.928	127.21	67.192
Total Receivables, Net	299.469	240.894	190.117	218.362	196.238
Accounts Receivable - Trade, Net	299.469	240.894	190.117	218.362	196.238
Total Inventory	147.549	119.924	96.298	108.011	100.868
Prepaid Expenses	28.772	29.155	26.122	14.478	20.7
Other Current Assets, Total	64.174	31.013	20.703	15.177	12.136
Total Assets	2210.76	2142.5	1824.5	1240.81	1081.24
Property/Plant/Equipment, Total - Net	132.013	119.69	114.187	110.376	51.5
Property/Plant/Equipment, Total - Gross	258.657	241.637	220.488	226.091	152.289
Accumulated Depreciation, Total	-126.644	-121.947	-106.301	-115.715	-100.789
Goodwill, Net	734.274	738.9	499.309	336.539	335.887
Intangibles, Net	323.666	374.611	262.238	209.937	200.505
Long Term Investments	32.924	18.391	22.156	19.75	17.082
Other Long Term Assets, Total	91.325	92.118	79.995	68.71	62.653
Total Current Liabilities	428.446	876.158	276.423	236.996	204.58
Accounts Payable	63.389	71.513	40.309	46.38	38.038
Accrued Expenses	224.912	192.335	125.56	91.972	69.829
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0	488.152			0
Other Current Liabilities, Total	140.145	124.158	110.554	98.644	96.713
Total Liabilities	1080.62	995.807	857.001	395.556	401.625
Total Long Term Debt	566.571	0	467.201	50	135.417
Long Term Debt	566.571	0	467.201	50	135.417
Deferred Income Tax	2.095	51.705	39.633	39.09	41.484
Other Liabilities, Total	83.509	67.944	73.744	69.47	20.144
Total Equity	1130.14	1146.69	967.503	845.254	679.617
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Common Stock	0.055	0.054	0.053	0.051	0.05
Additional Paid-In Capital	1046.76	1024.58	920.359	780.931	678.041
Retained Earnings (Accumulated Deficit)	390.728	368.571	290.722	258.792	197.454
Treasury Stock - Common	-290.319	-238.109	-238.109	-185.074	-185.074
Other Equity, Total	-17.087	-8.407	-5.522	-9.446	-10.854
Total Liabilities & Shareholders’ Equity	2210.76	2142.5	1824.5	1240.81	1081.24
Total Common Shares Outstanding	44.747	44.179	42.783	42.132	40.335
Note Receivable - Long Term	14.744	18.084	17.205	12.26	16.481
Short Term Investments	11.486	10.665	10.246

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	913.751	881.361	934.969	881.812	849.132
Cash and Short Term Investments	473.525	444.971	351.466	341.848	278.988
Cash & Equivalents	446.84	399.464	340.413	330.362	266.402
Short Term Investments	26.685	45.507	11.053	11.486	12.586
Total Receivables, Net	272.584	273.899	322.073	299.469	354.098
Accounts Receivable - Trade, Net	272.584	273.899	322.073	299.469	354.098
Total Inventory	116.144	130.577	141.156	147.549	147.096
Prepaid Expenses	28.072	23.577	28.075	28.772	26.708
Other Current Assets, Total	23.426	8.337	92.199	64.174	42.242
Total Assets	2221.57	2193.87	2250.84	2210.76	2179.69
Property/Plant/Equipment, Total - Net	132.324	130.91	126.601	132.013	132.489
Property/Plant/Equipment, Total - Gross	270.283	269.462	258.735	258.657	255.308
Accumulated Depreciation, Total	-137.959	-138.552	-132.134	-126.644	-122.819
Goodwill, Net	734.328	735.523	734.895	734.274	731.294
Intangibles, Net	288.733	299.832	311.803	323.666	336.19
Long Term Investments	41.631	35.039	32.744	32.924	33.807
Note Receivable - Long Term	13.159	15.132	13.491	14.744	13.815
Other Long Term Assets, Total	97.649	96.075	96.335	91.325	82.958
Total Current Liabilities	369.361	370.157	453.968	428.446	376.681
Accounts Payable	49.92	47.192	63.407	63.389	73.517
Accrued Expenses	169.723	174.479	225.961	224.912	167.698
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	149.718	148.486	164.6	140.145	135.466
Total Liabilities	1034.14	1030.31	1108.3	1080.62	1044.29
Total Long Term Debt	568.887	568.114	567.342	566.571	565.803
Long Term Debt	568.887	568.114	567.342	566.571	565.803
Deferred Income Tax	1.565	1.511	1.558	2.095	16.14
Other Liabilities, Total	94.326	90.525	85.429	83.509	85.666
Total Equity	1187.44	1163.56	1142.54	1130.14	1135.4
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Common Stock	0.056	0.056	0.055	0.055	0.055
Additional Paid-In Capital	1110.1	1088.82	1072.69	1046.76	1030.67
Retained Earnings (Accumulated Deficit)	384.732	379.179	375.728	390.728	419.136
Treasury Stock - Common	-290.319	-290.319	-290.319	-290.319	-290.319
Other Equity, Total	-17.129	-14.176	-15.608	-17.087	-24.142
Total Liabilities & Shareholders’ Equity	2221.57	2193.87	2250.84	2210.76	2179.69
Total Common Shares Outstanding	45.463	45.205	45.069	44.747	44.646
Current Port. of LT Debt/Capital Leases		0		0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	5.648	77.849	32.194	61.338	37.729
Cash From Operating Activities	77.781	231.809	185.87	145.008	103.966
Cash From Operating Activities	86.931	72.99	61.067	53.559	51.35
Deferred Taxes	-37.316	-3.272	-6.546	-1.339	-5.705
Non-Cash Items	95.984	87.582	61.855	47.26	31.31
Cash Taxes Paid	19.005	-1.733	10.343	7.761	3.489
Cash Interest Paid	1.438	1.917	0.522	3.582	7.487
Changes in Working Capital	-73.466	-3.34	37.3	-15.81	-10.718
Cash From Investing Activities	-58.669	-412.498	-279.866	-61.664	-54.374
Capital Expenditures	-60.74	-58.335	-54.866	-61.664	-54.374
Other Investing Cash Flow Items, Total	2.071	-354.163	-225	0	0
Cash From Financing Activities	-20.953	47.363	456.269	-23.479	-13.597
Financing Cash Flow Items	-8.925	-19.985	-5.296	-11.991	-6.775
Issuance (Retirement) of Stock, Net	-12.028	67.348	52.525	78.512	70.178
Issuance (Retirement) of Debt, Net	0	0	409.04	-90	-77
Foreign Exchange Effects	-0.944	-0.974	0.437	0.153	-1.227
Net Change in Cash	-2.785	-134.3	362.71	60.018	34.768

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-15	5.648	34.056	17.282	8.213
Cash From Operating Activities	12.77	77.781	-4.372	-25.547	-15.996
Cash From Operating Activities	21.974	86.931	64.843	43.017	21.124
Deferred Taxes	-7.77	-37.316	-17.061	-9.506	-4.858
Non-Cash Items	25.952	95.984	69.282	47.394	22.306
Changes in Working Capital	-12.386	-73.466	-155.492	-123.734	-62.781
Cash From Investing Activities	-13.64	-58.669	-41.417	-25.55	-18.733
Capital Expenditures	-13.64	-60.74	-43.509	-27.642	-15.341
Cash From Financing Activities	3.862	-20.953	-24.515	-33.571	-32.119
Financing Cash Flow Items	-8.252	-8.925	-11.844	-2.484	1.14
Issuance (Retirement) of Stock, Net	12.114	-12.028	-12.671	-31.087	-33.259
Issuance (Retirement) of Debt, Net		0	0
Foreign Exchange Effects	0.176	-0.944	-1.425	-2.123	-0.411
Net Change in Cash	3.168	-2.785	-71.729	-86.791	-67.259
Other Investing Cash Flow Items, Total	0	2.071	2.092	2.092	-3.392

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Omnicell Company profile

About Omnicell, Inc.

Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. Its point-of-care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company's Omnicell Interface Software provides interface and integration between its medication-use products or its supply products and a healthcare facility’s in-house information management systems. Its Central Pharmacy IV Compounding Service offers a comprehensive service model inclusive of IV robotic technology, data analytic tools, and clinical support for insourced sterile compounding programs.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Omnicell, Inc. revenues increased 27% to $1.13B. Net income increased from $32.2M to $77.8M. Revenues reflect Connected devices, software licenses, and other segment increase of 32% to $739.1M, SaaS, subscription software, and technology-enabled services segment increase from $53.8M to $112.5M, United States segment increase of 28% to $1.02B, Rest of the World segment increase of 18% to $111.2M.

Equity composition

Common Stock $.001 Par, 12/10, 100M auth., 37,148,706 issd. 4,121,123 shs. in Treas. @$65.1M. Insiders own 2.25%. Initial Public Offering: 8/07/01, 6Mshares @ $7 by U.S. Bancorp Piper Jaffray. 7/01 1-for-1.6 stock split. *NOTE: 8/01, the Company changed it's name from Omnicell.com.

Industry:

Medical Software & Technology Services

4220 North Freeway
FORT WORTH
TEXAS 76137
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024